Study Confirms Targeted Sensitivity of COVID-19 Test
Filed with ASX · · 3 pages · English
• Operon study results demonstrate high sensitivity of AnteoTech COVID-19 Antigen Rapid Test • 9 of 25 positive samples in the study PRC tested above Ct 30 • Next steps include continued work with Operon to finalise lower limit of detection AnteoTech Ltd (ASX: ADO) (“AnteoTech” or “the Company”) is pleased to announce that it has received the results of an independent validation study of the Anteo
Earlier from AnteoTech
- AnteoTech Achieve ISO-13485 Certification
- AnteoTech COVID-19 Antigen Test Progress Update
- Preliminary Final Report
- AnteoTech Secures $3.76M Option Underwriting Agreement
- AnteoTech Developing Multiplex Test for COVID-19
Later from AnteoTech
- AnteoTech Freeze Design of COVID 19 Test
- $1.19 million R&D Tax Incentive Refund Received
- $3.9M Options Exercise Complete
- AnteoTech Progresses COVID-19 Test Toward Market Launch
- Up to $1.4m in Qld Grant for COVID-19 test development
Follow AnteoTech into a list and get an email when it puts out news.
Follow AnteoTech